Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
Verlagsversion
DOI
PMC
 |
Open Access Gold (Paid Option) |
|
möglich sobald bei der ZB eingereicht worden ist.
The molecular pharmacology of glucagon agonists in diabetes and obesity.
Peptides 165:171003 (2023)
Verlagsversion
DOI
PMC
Within recent decades glucagon receptor (GcgR) agonism has drawn attention as a therapeutic tool for the treatment of type 2 diabetes and obesity. In both mice and humans, glucagon administration enhances energy expenditure and suppresses food intake suggesting a promising metabolic utility. Therefore synthetic optimization of glucagon-based pharmacology to further resolve the physiological and cellular underpinnings mediating these effects has advanced. Chemical modifications to the glucagon sequence have allowed for greater peptide solubility, stability, circulating half-life, and understanding of the structure-function potential behind partial and "super"-agonists. The knowledge gained from such modifications has provided a basis for the development of long-acting glucagon analogues, chimeric unimolecular dual- and tri-agonists, and novel strategies for nuclear hormone targeting into glucagon receptor-expressing tissues. In this review, we summarize the developments leading toward the current advanced state of glucagon-based pharmacology, while highlighting the associated biological and therapeutic effects in the context of diabetes and obesity.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Biased Agonism ; Diabetes ; Dual-agonists ; Glucagon ; Obesity ; Pharmacology ; Tri-agonists; Bioactive Enteroglucagon Oxyntomodulin; Receptor Antagonist Ly2409021; Hepatic Glucose-production; Reduces Food-intake; Body-weight Gain; Blood-glucose; Energy-expenditure; Insulin-secretion; Amino-acids; Cyclic-amp
ISSN (print) / ISBN
0196-9781
e-ISSN
1873-5169
Zeitschrift
Peptides
Quellenangaben
Band: 165,
Artikelnummer: 171003
Verlag
Elsevier
Verlagsort
New York, NY
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Diabetes and Obesity (IDO)
Förderungen
German Center for Diabetes Research (DZD e.V.)
German Research Foundation
European Research Council (ERC) within the ERC CoG Trusted
German Research Foundation
European Research Council (ERC) within the ERC CoG Trusted